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Abstract
Background. This study has two main objectives: to describe the prevalence of undetected
chronic obstructive pulmonary disease (COPD) in a clinical sample of smokers with severe
mental illness (SMI), and to assess the value of the Tobacco Intensive Motivational Estimated
Risk tool, which informs smokers of their respiratory risk and uses brief text messages to
reinforce intervention.
Method. A multicenter, randomized, open-label, and active-controlled clinical trial, with a
12-month follow-up. Outpatients with schizophrenia (SZ) and bipolar disorder were random-
ized either to the experimental group—studied by spirometry and informed of their calculated
lung age and degree of obstruction (if any)—or to the active control group, who followed the
5 A’s intervention.
Results. The study sample consisted of 160 patients (71.9% SZ), 78.1% of whom completed the
12-month follow-up. Of the patients who completed the spirometry test, 23.9% showed evidence
of COPD (77.8% in moderate or severe stages). TIMER was associated with a significant
reduction in tobacco use at week 12 and in the long term, 21.9% of patients reduced consumption
and 14.6% at least halved it. At week 48, six patients (7.3%) allocated to the experimental group
achieved the seven-day smoking abstinence confirmed by CO (primary outcome in terms of
efficacy), compared to three (3.8%) in the control group.
Conclusion. In this clinical pilot trial, one in four outpatients with an SMI who smoked had
undiagnosed COPD. An intensive intervention tool favors the early detection of COPD and
maintains its efficacy to quit smoking, compared with the standard 5 A’s intervention.
Background
High premature mortality rates severely reduce life expectancy in people with severe mental
illness (SMI) [1–3], the main causes being cardiovascular and respiratory diseases–in particular
chronic obstructive pulmonary disease (COPD) and pneumonia [4]. Tobacco smoking is amajor
cause of COPD. Compared to the general population, the COPDmortality hazard ratio is three to
nine times higher for individuals with bipolar disorder (BD) and schizophrenia (SZ) [5–7].
With consumption rates similar to those of the general population 50 years ago [8], smoking is
the highest preventable risk factor for premature mortality in SMI [9]. People with an SMI
diagnosis and tobacco addiction are smokers with a higher dependency level, more intense
smoking habits, for example, with a greater depth of puff, and a lower probability of quitting
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far been based on surveys and population studies. Therefore, very
little evidence on the onset of lung damage and the possibilities of
early diagnosis in SMI is available [13].
Safe and effective pharmacological approaches exist for treating
smoking in SMI [14,15]. Persuading as many patients as possible to
undergo treatment remains as one of the key challenges [16]. The
preparation phase, which boosts motivation and schedules the new
attempt, is an essential step [17]. Nowadays, more personalized
interventions with specific designs are recommended to achieve
that goal [18].
New tools, such as using personalized information and mobile
technology, have proved effective in promoting health and gener-
ating healthy behavior [19]. In smoking treatments in the general
population, informing the subject about their individual risks using
lung scans, genetic tests, or spirometry, encourages new attempts to
quit, helps to reduce consumption, and can increase cessation rates
[20–25]. In patients with SZ or BD, who are usually less aware of the
risks for their health [26,27], the efficacy of giving personalized
information about risk and prevention has not been fully explored.
Even themost basic feature ofmobile technology, the shortmessage
service (SMS), can reach devices everywhere and has been shown to
generate and maintain motivation to quit smoking [28].
Patients with SMI have less access to preventive health care
[29] as well as a pressing need to advance toward smoking
cessation. The Tobacco Intensive Motivational Estimated Risk
tool (TIMER) is based on the structure of the 5 A’s, which is
the standard guidelines for intervention in clinical practice (Ask,
Advise, Assess, Assist, and Arrange) [22]. Here, it reports spi-
rometry results, the Gold Standard in the study of lung function
[30], to inform the patient of their respiratory risk and it keeps
the message going via SMS technology.
This is a clinical pilot trial with two main objectives: (a) to
evaluate previously undiagnosed lung damage in a sample of
smokers with SZ and BD; and (b) to analyze the effectiveness of
the TIMER tool to help smoking cessation, reduce consumption,
and generate attempts to quit, compared to the 5 A’s reference
intervention. It could present an opportunity to promote the early
diagnosis of COPD in the clinical context of community care,
without losing its value as a way of activating the quitting process.
Methods
Study design and settings
This was a multicenter, randomized, active-controlled, open-label,
pilot trial with a 12-month follow-up. The study was carried out in
nine mental health centers (MHC) in urban and rural community
settings in four provinces of Andalusia—Córdoba, Jaén, Málaga,
and Granada—in southern Spain. The study protocol (11/2016)
was approved by the Research and Ethics Committee of the Reina
Sofía University Hospital (HURS) in Córdoba. All the participants
gave their written informed consent before randomization. The
ClinicalTrials.gov identifier was NTC03583203.
Sample recruitment and randomization
Over a 6-month period, all consecutive outpatients at the MHCs
who met the selection criteria were invited to participate in the
study.
Inclusion criteria
1. Aged between 40 and 70 years.
2. Patients diagnosed with SZ or BD, according to the Diagnostic
and Statistical Manual of Mental Disorders, 4th edition, text
revision (DSM-IV-TR) [31].
3. Active smokers (current consumption of at least 10 cigarettes
per day (CPD) with a cumulative consumption of at least
10 packs/year.
4. Clinical stability, which was psychometrically confirmed for
participants with BD ([Hamilton Rating Scale for Depression
[32] total score lower than 14 and Young Mania Rating Scale
[33] total score lower than 6]) and SZ ([Positive and Negative
Syndrome Scale [34] total score lower than 70]).
Exclusion criteria
1. Patients with a current or previous diagnosis of respiratory
conditions.
2. Existence of any pathology which makes it inadvisable to
perform spirometry.
3. Patients who, due to their intellectual disability or other psy-
chiatric disorder, do not understand study procedures or
cannot adequately perform spirometry.
The randomization was carried out using the Redcap program [35],
as implemented by the Technological and Bioinformatic Innova-
tion Unit at the IMIBIC (Maimónides Institute of Biomedical
Research) in Córdoba, Spain. Randomization was centralized, per-
formed in permuted blocks, and stratified by MHC, age, gender,
and pathology.
Intervention
The experimental and control interventions were performed by the
same psychiatrists and mental health nurses in charge of patients’
routine follow-ups at each MHC. They received additional training
from experts from the addiction treatment network and specialists
in functional tests from the Pneumology Service at the HURS, in
Córdoba.
In the experimental intervention, personalized information
about the lung damage and prevention opportunities were
included, which allowed patients to compare their lung age with
chronological age. Moreover, patients received information regard-
ing the evidence of undetected COPD (or lack thereof) and its
staging. For further details, please see the supplementary material.
Outcomes
Lung damage
1. Primary outcome: the presence of COPD confirmed after
bronchodilation (Forced Expiratory Volume in first second
(FEV1)/forced vital capacity (FVC)<0.7) and COPD staging
following the Global Initiative for Chronic Obstructive Lung
Disease [36]—1(mild): FEV1>80%; 2 (moderate): 50%<FEV1
<80%; 3 (severe): 30%<FEV1<50%; 4 (life-threatening): FEV1
<30%—and the combined classification—lung function and
respiratory clinical condition—for COPD (see Table 4).
2. Secondary outcome: percentage of FEV1 compared with
expected level, based on the Fletcher and Peto model [37];
and the presence of restrictive pattern (FVC<80% and FEV1/
FVC>70%).
Efficacy
1. Primary outcome: smoking cessation at 48weeks from the
intervention (self-reported abstinence for the past 7 days,
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confirmed by CO-oximetry with expired carbon monoxide
(CO)< 10 particles per million (ppm)).
2. Secondary outcomes: (a) smoking cessation at 3 and 6months;
(b) reduction in the tobacco consumed, as self-reported by the
patient and confirmed by expired CO at 12, 24, and 48weeks;
and (c) number of quit attempts—at least 24 h smoking-free—
over the follow-up.
Follow-up and assessments
Subjects from the two study armswere evaluated four times. The first
visit (baseline) was scheduled before the intervention, and follow-up
visits at 12, 24, and 48weeks after the intervention (see Figure 1). In
addition, all patients attended regularly scheduled appointmentswith
their psychiatrists as part of their usual clinical follow-up.
The sociodemographic and clinical variables, smoking habit
data, motivation levels, number of attempts to quit, history of other
substance use, medical comorbidities, and anthropometric mea-
surements were collected, as specified in the scheduled task in the
supplementary material. For further details, please see the previ-
ously published protocol [38].
The descriptive variables of the lung damage study—volumes and
clinical respiratory observations—were obtained from the two clin-
ical groups: (a) the subjects in the intervention arm at the baseline
visit (here the data were used as personalized information on lung
risk and as a basis for the assessed intervention); (b) those patients in
the control arm who had finished the follow-up and were interested
in learning about their lung function. The results describing lung
damage are the summary of the data from these two groups.
Statistical analysis
Continuous variables are described as mean and standard devia-
tions values, the categorical variables as frequencies and
proportions. For the sample description, the Mann–Whitney and
Chi-square tests were used to compare continuous variables
between the groups and over time, as appropriate. The Last Obser-
vation Carried Forward method was used as a denominator of
proportions, which refers to the total number of randomized
patients.
A linear mixed-effects model was performed to evaluate the
changes in the short-term reduction in smoking (from baseline to
12weeks) and in the long-term reduction in smoking (from base-
line to 48weeks) with time, socio-demographics, smoking habit,
and clinical data taken as fixed effects, and a random intercept and
random slope effects. The variables which are clinically considered
to exert a possible effect on reduction in smoking were introduced
into a variable selection in a multivariate model, comparing the
nested models using the log-likelihood values.
The linear mixed-effects models deal with missing values and
measurement error taking into account the between- and within-
subject variability. The variance–covariance structure was fixed to
an unstructured matrix and the random effects and error terms
were assumed to have a normal distribution.
For the primary goal of efficacy and estimating abstinence at 12
months of 3 and 15% in the control and experimental arms, a
sample size calculation of 86 patients per arm was made, with an
added 20% for possible losses during follow-up (formore details see
the published protocol) [38]. To explore the possible risk factors for
the obstructive pattern—age, sex, psychiatric diagnosis, economic
status, size of city of residence, level of smoking dependence,
combined consumption of tobacco and cannabis, cohabitation with
other smokers, antipsychotic treatment, abdominal circumference,
body mass index, diabetes, and dyslipidemia—and due to the small
sample size (for having a greater number of parameters than the
sample), we performed just a univariate logistic regression for all
possible characteristics of patients. All the analyses were performed
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Figure 1. Flow diagram in the study design. Patient disposition.
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considered as statistically significant. The results are presented as
Odds Ratios and 95% CI only for the statistically significant
variables.
Results
A total of 220 patients attending their scheduled appointments were
informed about the study procedures. Of them, 182 patients met all
the criteria for inclusion and none for exclusion, and signed the
informed consent. Given that 22 patients withdrew their consent
before enrolment, 160 patients were finally randomized. The final
sample size was somewhat below that calculated at the beginning.
Taking as reference the estimated abstinence rates at 12months of
3 and 15% in the control and experimental arms, respectively, the
post-hoc statistical power of this study was 77% with 95% confi-
dence intervals.
The final sample of the present study was made up of
160 patients, who were randomized to the EG (n= 82) and the
CG (n=78). Of the total sample, in 115 (71.9%) diagnosis was SZ
and 45 (28.1%) was BD. The dropout rate was 21.87%: seven cases
(4.37%) due to hospital admission after a relapse, and the remaining
28 (17.5%) who missed their appointments (Figure 1 shows the
patients’ disposition).
The demographic, clinical, anthropometric, and smoking char-
acteristics at baseline are shown in Table 1. There were no signif-
icant differences between groups. Two patients in the CG (Nicotine
replacement therapy (TSN)) and two in the EG (1TSN and 1
Varenicline) were under pharmacological treatment.
Table 1. Sociodemographic, clinical, and smoking characteristics at baseline.












(N = 78) p
Mean age [mean (SD)] 48.15 (6.12) 49.22 (5.45) 48.45 (5.92) 47.93 (5.30) 53.18 (6.46) 49.41 (6.09) 0.353a
Gender [n (%)] 0.699b
Male 47 (79.7) 10 (43.5) 57 (69.5) 42 (75) 10 (45.5) 52 (66.7)
Female 12 (29.3) 13 (56.5) 25 (30.5) 14 (25) 12 (54.5) 26 (33.3)
Marital status [n (%)] 0.207b
Never married 39 (66.1) 6 (26.1) 45 (54.9) 43 (76.8) 5 (22.7) 48 (61.5)
Married or cohabiting 10 (16.9) 11 (47.8) 21 (25.6) 4 (7.1) 8 (36.3) 12 (15.4)
Widowed or
separated/divorced
10 (16.9) 6 (26.1) 16 (19.5) 9 (16.1) 9 (40.9) 18 (23.1)
Educational level [n (%)] 0.653b
Without studies 6 (10.2) 1 (4.3) 7 (8.5) 6 (10.7) 1 (4.5) 7 (9.0)
Primary school 30 (50.8) 8 (34.8) 38 (46.3) 22 (39.3) 9 (40.9) 31 (39.7)
Secondary school 19 (32.2) 12 (52.2) 31 (37.8) 21 (37.5) 9 (40.9) 30 (38.5)
University 4 (6.8) 2 (8.7) 6 (7.3) 7 (12.5) 3 (13.6) 10 (12.8)
Work status [n (%)] 0.281b
Unemployed 7 (11.9) 4 (14.4) 11 (13.4) 3 (5.4) 2 (9.1) 5 (6.4)
Working part or full-
time
4 (6.8) 5 (21.7) 9 (10.9) 2 (3.6) 3 (13.6) 5 (6.4)
Disabled temporary 0 0 0 0 0 2 (2.6)
Disabled permanent
(mental disease)
47 (79.7) 12 (52.1) 58 (70.7) 49 (87.5) 13 (59.1) 62 (79.5)
Others 1 (1.7) 2 (8.7) 3 (3.7) 2 (3.6) 2 (9) 4 (5.1)
% Incomec [mean (SD)] 74.49 (36.23) 89.29 (72.18) 82.12 (48.12) 98.77 (59.37) 92.29 (66.23) 97.05 (60.79) 0.460a
Population size [n (%)] 0.921b
<10,000 21 (35.6) 11 (47.8) 32 (39.0) 21 (37.5) 8 (36.4) 29 (37.2)
10,000–50,000 15 (25.4) 5 (21.7) 20 (24.4) 13 (23.2) 7 (31.8) 20 (25.6)
50,000–250,000 12 (20.3) 2 (8.7) 14 (17.1) 12 (21.4) 4 (18.2) 16 (20.5)
>250,000 11 (18.6) 5 (21.7) 16 (19.5) 10 (17.9) 3 (13.6) 13 (16.7)
Years of consumption
[mean (SD)]
30.10 (8.26) 31.32 (8.39) 30.43 (8.25) 30.37 (7.28) 34.68 (7.52) 31.59 (7.55) 0.351a
Pack/year [mean (SD)] 34.98 (16.57) 34.52 (15.41) 34.85 (16.16) 35.37 (20.79) 32.11 (15.97) 34.45 (19.51) 0.495a
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We decided to expose in the first place the efficacy of TIMER
tool data and in the second place the results of lung damage because
it can be better to understand globally the aims of the study.
Efficacy
Abstinence
Regarding the primary efficacy outcome in the long-term (week
48), 7.32% (n=6) of the EG and 3.85% (n= 3) of the CG achieved
abstinence at week 48. At the short-term, 7.32% (n=6) of the EG
and 2.56% (n= 2) of the CG at week 12, and 8.54% (n=7) of the EG
and 5.13% (n=4) of the CG at week 24, achieved abstinence. No
statistically significant differences were observed between the
groups at any point during the follow-up (Table 2).
Tobacco reduction
At week 12, both the TIMER and the 5A’s intervention had gener-
ated a significant reduction in CPD (paired test, p< 0.01) and
expired CO (paired test, p< 0.01).
These short-term significant reductions in expired CO and
CPD were confirmed by a multivariate linear mixed-effects model
(negative time effect, p< 0.001) adjusted by other covariates
which were added to the model by variable selection (see
Table 3).
Table 1. Continued












(N = 78) p
Expired COd [mean (SD)] 18.65 (7.63) 15.43 (8.42) 17.80 (8.45) 19.39 (9.09) 17.36 (6.34) 16.93 (9.00) 0.433a
Cigarettes per day [mean
(SD)]
23.41 (10.28) 20.18 (8.34) 21.56 (10.01) 23.68 (12.4) 18.45 (7.88) 20.73 (12.17) 0.338a
FTNDe [mean (SD)] 5.91 (2.01) 5.39 (2.31) 5.76 (2.09) 5.92 (2.29) 5.41 (2.26) 5.77 (2.28) 0.886a
Length of illness, years
[mean (SD)]
23.76 (8.05) 21.56 (10.14) 23.15 (8.68) 25.18 (7.78) 21.90 (9.19) 24.25 (8.27) 0.439a
PANSSf total [mean (SD)] 48.79 (11.13) — 48.79 (11.13) 50.05 (9.71) — 50.05 (9.71) 0.509a
HDRSg [mean (SD)] — 2.81 (3.36) 2.81 (3.36) — 4.71 (4.19) 4.71 (4.19) 0.064a
YMRSh [mean (SD)] — 0.83 (1.40) 0.83 (1.40) — 1.47 (2.09) 1.47 (2.09) 0.459a
HARSi [mean (SD)] 5.49 (5.10) 4.78 (4.50) 5.29 (4.92) 6.13 (5.70) 8.25 (8.96) 6.70 (6.74) 0.264a
GAESj [mean (SD)] 65.17 (13.23) 75.00 (12.34) 67.96 (13.66) 63.46 (11.57) 72.38 (9.30) 65.90 (11.65) 0.366a
Body Mass Index (BMI)
[mean (SD)]
30.27 (5.36) 31.22 (6.02) 30.54 (5.53) 30.10 (5.92) 31.08 (6.31) 30.38 (6.01) 0.893a
Abdominal perimeter
[mean (SD)]





17 (28.8) 2 (8.7) 19 (23.2) 5 (8.9) 5 (23.8) 10 (12.8) 0.233b
Standard drink unit [mean
(SD)]




18 (30.5) 4 (17.4) 22 (26.8) 18 (32.1) 7 (31.8) 25 (32.1) 0.469b
Joint/year [mean (SD)] 20.69 (35.84) 83.30 (95.86) 32.08 (54.43) 10.76 (14.23) 20.44 (21.89) 13.71 (17.02) 0.982a
Arterial hypertension,
Yes [n (%)]
5 (8.5) 2 (8.7) 7 (8.5) 6 (10.7) 4 (18.2) 10 (12.8) 0.379b
Diabetes mellitus, Yes
[n (%)]
7 (11.9) 4 (17.4) 11 (13.4) 6 (10.7) 3 (13.6) 9 (11.5) 0.720b
Dislipemia, Yes [n (%)] 10 (16.9) 5 (21.7) 15 (18.3) 12 (21.4) 3 (13.6) 15 (19.2) 0.879b
Evaluation of the SMS
[mean (SD)]
75.31 (18.01) 70.56 (19.70) 73.92 (18.46)
Abbreviations: BMI, Body Mass Index; SMS, short message service.aU Mann–Whitney.
bChi-square test.
c% income: % respect for the interprofessional minimum salary in Spain (2017):707.06€.
dCO: expired carbon monoxide.
eFTND: Fagerström Test for Nicotine Dependence.
fPANSS: Positive and Negative Syndrome Scale.
gHDRS: Hamilton Rating Scale for Depression.
hYMRS: Young Mania Rating Scale.
iHARS: Hamilton Anxiety Rating Scale.
jGAES: Global Activity Evaluation Scale.
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Mixed-effects models indicated that evolution in both CO
levels and CPD was significant over time (time effect, p< 0.001,
Cohen’s d=0.38) and was also strongly predicted by the depen-
dence level at baseline (p< 0.001, Cohen’s d=0.15). However,
these significant reductions over time were not observed in the
long-term multivariate model where was analyzed the evolution
from baseline to 48weeks.
At week 12, 32 patients (39.02%) in the EG had reduced their
CPD and expired CO, whereas 13 patients (15.85%) achieved a
reduction in at least 50% CPD. At week 24, the combined reduc-
tion was observed in 25 (30.49%) patients and a reduction in at
least 50% CPD was achieved by 12 EG patients (14.63%). At
endpoint, 18 patients (21.95%) had maintained a reduction in
CPD and expired CO, whereas 12 patients (14.63%) had a reduc-
tion in at least 50% CPD. Significant differences from the CG in
several measurements were not found at any visit (see Table 2 and
Figure 2 for more details).
Attempts to quit
In the EG, 18.29% (n= 15) of the patientsmade at least one attempt
to abandon during the first 12weeks of follow-up, without signif-
icant differences from the CG (see Table 2). Between weeks 12 and
24, a significantly greater number of patients achieved this goal in
the EG (n=15; 18.29%) than in the CG (n=7; 8.97%) (p= 0.008).
In the final observation period, between weeks 24 and 48, 13.41%
(n= 11) made at least one attempt in the EG, without significant
differences from the CG.
Spirometry results
A total of 113 patients—mean age of 49.38 (5.99) consuming 36.61
(18.08) packs/year—completed the pulmonary function measure-
ments with internal and external validation according to the
scheduled protocol (see Jaen-Moreno 2019) [38]. Of these,
82 EGpatients were studied at the baseline visit and 31CGpatients
wished to be informed about their lung function at the end of
follow-up. The results of the spirometry tests are presented in
Table 4.
A total of 27 patients (23.9%) were diagnosed with COPD,
regardless of psychiatric diagnoses (chi-square test, p=0.176), and
sex (chi-square test, p= 0.163). Of these, six patients (22.2%) were
in theGOLD 1 stage, 20 (74.1%) inGOLD 2 and 1 (3.7%) inGOLD
three stages. In the combined evaluation (presence of respiratory
symptoms and lung function), 23 (85.2%) patients met stage A
criteria (low risk, low symptoms), 3 (11.1%) patients stage B (low
risk, more symptoms), and 1 (3.7%) stage D (high risk, more
symptoms) (see Table 4).
Univariate analysis with a logistic regressionmodel (OR 1.77CI
95% 1,017–7.54 p=0.046) showed that living with other smokers
increased the risk of COPD. None of the other analyzed variables
showed any statistically significant associations.
Out of the 86 patients who did not meet COPD criteria,
23 (26.7%) had an FEV1< 80% than expected.
Security protocol and satisfaction
At study endpoint, EG patients rated the quality and convenience
of the SMS as 73.92 (SD 18.46), out of 100. Of the 82 subjects who
took part in the intervention, 10 had no mobile phone, and these
were called by a researcher using a landline. No subjects asked for
the SMS or calls to be stopped, despite this being included as one of










































































































































































































































































































































































































































































































































































6 M. J. Jaen-Moreno et al.
Discussion
This pilot trial had two main objectives: to describe the prevalence
of undetected COPD in a clinical sample of smokers with SMI, and
to assess the value of the TIMER tool, which informs smokers of
their respiratory risk and uses brief text messages to reinforce the
intervention.
Regarding the lung damage goal, we found that in a sample of
smokers with schizophrenia and BD, spirometry enabled us to
diagnose COPD—confirmed by post-bronchodilation values—in
almost one in four patients studied (23.9%), regardless of psychi-
atric disorder. In turn, the majority of them (78%) presented
moderate or severe stages (two and three of GOLD) and in most
cases (85%), COPD was evolving silently.
In relation with the efficacy outcome, the TIMER tool, which
reports individual respiratory risks and the possibilities of preven-
tion, promotes the detection of COPD in a sample of outpatients
with SMI, generates attempts and significantly reduces consump-
tion in the short term. Still, it does not show a significant difference
with the control intervention and current reference tool in the
clinical guidelines, in the primary goal of smoking cessation or
any other outcome, in the long term.
Lung damage
So far, several surveys and population studies have reported a
higher presence of COPD in individuals with schizophrenia
(OR 1.57, 1.44–1.72) and BD (1.55, 1.45–1.67) [13]. However,
the nature of this relationship remains uncertain [39]. To our
knowledge, this is the first study on the presence of undiagnosed
COPD by means of spirometry and its relationship with several
risk variables for lung function in a representative sample of
outpatients with schizophrenia and BD attending their sched-
uled appointments. Previous studies have explored this relation-
ship in previously diagnosed patients obtained from a
population survey [40]. In this case, they found a higher
prevalence of COPD in both BD (OR> 2) and schizophrenia
(OR> 4), although COPD was significantly associated with
smoking only in this last group.
COPD is a disease mainly associated with accumulated smoking
and age but also influenced by living conditions [36]. The world-
wide prevalence of COPD varies considerably [41] with an esti-
mated 4% of COPD in smokers under 50 years of age [42]. Taken
into account the age and tobacco consumption (>30 packs/year) of
our sample, the prevalence of COPD for the Spanish population is
9% [43]. In addition to the severity of smoking, lower educational
level and poor living conditionsmay expose patients with an SMI to
an increased risk of developing COPD.
Of the patients not diagnosed with COPD in the present study,
26.7% had an FEV1 lower than 80% of the expected rate. The lower
FEV1 has been demonstrated to be a predictor of mortality due to
cardiovascular, respiratory, and oncological causes, and it has been
previously described in patients with SMI [44]. Moreover, FEV1
may explain at least in part an increased risk for a restrictive pattern
(a decrease in FEV1 due to a lower FVC) and mainly related to
central obesity and metabolic syndrome, which are common
comorbidities in these patients [45,46].
Table 3. Linear mixed effects models to evaluate the changes in the reduction of tobacco over time (from baseline (Visit 0) to 12weeks observations).
Coefficient Standard error t-Value p
Model of COa
(Intercept) 9.800 1.497 6.542 <0.001
Time (baseline-12weeks) 0.031 0.006 4.729 <0.001
FTNDb 1.466 0.238 6.141 <0.001
Model of cigarettes per day
(Intercept) 4.874 (1.781) 2.735 <0.001
Time (baseline-12weeks) 2.059 (0.377) 5.455 <0.001
FTND 3.199 (0.271) 11.797 <0.001
aCO: expired carbon monoxide.
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Figure 2. Effectiveness of the TIMER tool on smokers with an SMI.
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Early detection of COPD in smokers with an SMI should be
encouraged in order to increase their life expectancy. The
co-existence of severe stages of COPDmay worsen clinical outcomes
in those with schizophrenia. For instance, a greater number of
relapses leading to hospital admissions and a higher mortality rate
in the 30days after admission have been described [47]. Respiratory
diseases—principally COPD and pneumonia—are the second cause
of prematuremortality in this population [5,6]. Indeed, patients with
schizophrenia aged between 35 and 54years have a risk of 11 times
greater than that of the general population [48].Moreover, having an
obstructive pathology increases the development of comorbidities at
an earlier age as well as the risk of premature mortality due to
cardiovascular and oncological diseases [49].
The TIMER intervention
For the first time, smokers with SMIwere offered the opportunity to
learn about their lung damage. In this case as an opportunity to
mobilize toward a change and evaluating the effect at the longitu-
dinal level through a randomized pilot trial, controlled with an
active comparator. The comparator chosen in this case was the 5A’s
intervention, which is the benchmark in clinical guidelines and far
exceeds the current care strategies in MHCs in Southern Spain,
which employ no more than 1 A [50].
The main goal of smoking cessation at week 48 and any other
long-term outcomes, did not reach significant differences com-
pared to the control intervention, 5 A’s. In real-world clinical
practice, when offered to all patients, without previous selection
for their motivation level, a tool designed to generate initial mobi-
lization without the guaranteed availability of pharmacological
treatment, achieves up to 8.54% abstinence at week 24 and 7.32%
by the end of follow-up. The goal of smoking cessation constitutes a
complex challenge that is particularly difficult to maintain in this
population. When pharmacological treatment was warranted to
SMI patients who are actively seeking treatment, success rates at 6
Table 4. Respiratory damage and spirometrics results.















FEV1a (SD) 2.90 (0.77) 2.39 (0.75) 2.76 (0.79) 2.92 (0.78) 2.46 (0.76) 2.80 (0.80)
% FEV1 (SD) 81.56 (17.36) 82.05 (13.92) 81.69 (16.46) 81.93 (17.92) 84.77 (16.36) 82.65 (17.50)
FVCb (SD) 3.92 (0.97) 3.25 (1.00) 3.75 (1.02) 3.91 (0.99) 3.35 (0.99) 3.77 (1.01)
% FVC (SD) 86.33 (15.48) 86.64 (12.47) 86.41 (14.68) 85.66 (16.01) 89.95 (15.77) 86.75 (15.99)
FEV1/FVC (%) (SD) 73.01 (10.20) 73.85 (7.63) 73.23 (9.56) 74.75 (7.76) 73.53 (8.51) 74.44 (7.93)
Schizophrenia Bipolar disorder Overall
COPDc Yes [n (%)] 19 (22.9%) 8 (26.6%) 27 (23.9%)
COPD [n (%)]
GOLD 1d 3 (15.8%) 3 (37.5%) 6 (22.2%)
GOLD 2 16 (84.2%) 4 (50.0%) 20 (74.1%)
GOLD 3 0 (0%) 1 (12.5%) 1 (3.7%)
Exacerbations last year
Yes [n (%)] 9 (47.4%) 7 (87.5%) 16 (59.3%)
CATe [n (%)]
<10 14 (73.7%) 4 (50%) 18 (66.7%)
>10 5 (26.3%) 4 (50%) 9 (33.3%)
mMRCf [n (%)]
Grado 0 8 (42.1%) 4 (50.0%) 12 (44.4%)
Grado 1 9 (47.4%) 3 (37.5%) 12 (44.4%)
Grado 2 2 (10.5%) 1 (12.5%) 3 (11.1%)
Combined COPD assessmentg [n (%)]
A 16 (84.2%) 7 (87.5%) 23 (85.2%)
B 2 (10.5%) 1 (12.5%) 3 (11.1%)
D 1 (5.3%) 0 (0.0%) 1 (3.7%)
aFEV1: Forced expiratory volume in the first second;
bFVC: Forced Vital Capacity
cCOPD: chronic obstructive pulmonary disease
dGOLD: Global Initiative for Chronic Obstructive Lung Disease
eCAT: COPD assessment test
fmMRC: Modified British Medical Research Council
gCombined COPD assessment: A (low risk, low symptoms): Gold 1–2, mMRC 0–1, CAT<10, exacerbations 0–1; B (low risk, more symptoms): Gold 1–2, mMRC > =2, CAT > = 10, exacerbations 0–1; C
(high risk, less symptoms): Gold 3–4, mMRC 0–1, CAT <10, exacerbations > = 2; D (high risk, more symptoms): Gold 3–4, mMRC >= 2, CAT > = 10, exacerbations > = 2.
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months were between 13 [14] and 15% [51] and at 12months were
between 10 and 26% [14,52,53].
Reducing tobacco consumption may provide either a stepping-
stone to smoking cessation [54], or benefits to mitigate the damage
[55]. TIMER, slowed only by the level of starting dependency,
generated a significant reduction in the average levels of expired
CO and decreased the tobacco consumption in nearly 4 in
10 patients, reported and objectified by expired CO. Half of these
patients sustained this reduction until the end of the intervention,
as well as 12months after. Moreover, 15% of the patients at least
halved the number of cigarettes smoked per day.
The TIMER tool used text messaging for the first 3months.
These types of messages have been shown to boost motivation in
the general population and may increase the chances of success
[28,56]. Indeed, in smoking treatment, a greater intensity of the
intervention increases the cessation rates [57]. The design used in
this study has not allowed differentiating separately the effect of the
damage information and the technological element. Messages were
rated as very satisfactory by patients, with none requesting them to
be interrupted.
In the current pilot trial, no significant differences between
interventions were observed during the follow-up. Although the
5 A’s intervention has been scarcely studied in SMI, it was associ-
ated with abstinence rates (4%), close to those described so far in
this population: 6% abstinence at 12months [58]. The two inter-
ventions have been limited by the lack of subsidies for pharmaco-
logical treatment: only two patients in each branch could access
treatment. The option of pharmacological treatment after the
motivational intervention was recommended to all patients. Even
so, it is not part of the clinical routine of our environment, it was not
available as a resource in the study and it was no publicly funded in
Spain at that time. In smoking, initial motivation and perceived
self-efficacy are predictors of initial progress (in a reduction of
consumption and attempts to quit), but not of long-term success
[59,60]. In the future, this type of intervention must be integrated
into multi-component programs [15].
We should be cautious in interpreting the present results,
which are based on a pilot trial with two main limitations. First,
the reduced sample size may have limited the likelihood to detect
a significant superiority of the motivational tool evaluated com-
pared to the standard intervention. Second, premature mortality
in this population is also linked to their economic vulnerability
and although the TIMER tool was expected to mobilize the
patient toward pharmacological treatment, the lack of available
pharmacological resources in the study setting curbed this possi-
bility.
Other limitations may have influenced the results of lung dam-
age and efficacy of the intervention. A 22% loss to follow-up was
observed, which was similar for both study arms and falls under the
usual rate in similar trials with this population [53]. The aim of
adapting the trial to a real clinical context reduced the visits, thus
limiting the opportunity for observation and not giving
the approach the right specificity and intensity it deserves due to
the severity of the addiction in SMI. Conversely, innovation and the
randomized and controlled design are among the study strengths.
Further studies are needed to confirm the reported prevalence
of undiagnosed COPD in clinical samples of patients with SMI.
Although spirometry is not considered as a screening test in
asymptomatic patients in the general population [36], the severity
of smoking, the conditions and lifestyle habits in this population,
their lack of preventive care [29] and the consequences of mor-
tality in a late diagnosis could all point to the importance of
studying lung function based on age ranges and accumulated
tobacco use. Clinical trials with a larger sample size that guaran-
tee a multicomponent approach will help to determine the real
motivational value of tools that inform SMI patients of their
chances of prevention.
To summarize, it was found that 24% of patients with SMI had
previously undiagnosed COPD and that a motivational tool, which
reports individual respiratory risks and is feasible in community
care, may allow an early detection of lung damage.
However, although it generates quit attempts and reduces con-
sumption in the short term, the TIMER tool did not significantly
differ from the control intervention 5 A’s, in the goal of smoking
cessation at 48weeks or any other long-term outcome.
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